Nicholas Short, MD
M.D. Anderson Cancer Center · MD Anderson Center · MD Anderson Cancer Center, Houston, Texas
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nicholas Short, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:40 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06930651 · A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid MalignanciesM.D. Anderson Cancer Center · recruiting · Myeloid Malignancies · principal investigator
- Ph1NCT06401603 · A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06308588 · Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · recruiting · Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT06235801 · A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Myeloid Leukemia · principal investigator
- Ph2NCT05285813 · A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent FailureM.D. Anderson Cancer Center · terminated · AML, MDS · principal investigator
- Ph1/Ph2NCT05211570 · AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAB Science · recruiting · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT05032183 · Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaM.D. Anderson Cancer Center · terminated · Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.